• CoreCivic posted net income of USD 37.9 million, or USD 0.38 per diluted share, in the quarter ended March 31, 2026, up from USD 25.1 million, or USD 0.23 per diluted share, a year earlier.
• Revenue climbed 25.8% to USD 614.7 million, driven by higher federal management revenue, which rose 48.4% to USD 358.1 million.
• Average compensated occupancy increased 2.6 percentage points to 79.6%, while revenue per compensated man-day rose to USD 116.53 from USD 102.71.
• Operating expenses rose to USD 467.7 million from USD 374.7 million, with salaries and benefits representing about 63% of total operating expenses.
• Subsequent to quarter end, CoreCivic acquired Clinical Solutions Pharmacy on April 1 in an all-cash deal with an initial purchase price of about USD 148 million, funded with cash on hand and Revolving Credit Facility borrowings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CoreCivic Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-211158), on May 07, 2026, and is solely responsible for the information contained therein.